Introduction: Crohn’s disease (CD) is a chronic, progressive inflammatory bowel disease characterized by transmural inflammation that can affect any segment of the gastrointestinal tract. It leads to cumulative bowel damage, strictures, and fistula formation, posing significant therapeutic challenges (1). Despite advances in biologic therapy, up to

Background Crohn’s disease (CD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract characterized by transmural inflammation leading to strictures, fistulae, and progressive bowel damage (1). Despite significant advances with biologic agents such as anti-TNF, anti-integrin, and IL-12/23 inhibitors, many patients experience s

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  FDA Approves Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma On October 8, 2025, the U.S. Food and Drug Administration approved cemiplimab as adjuvant therapy for adults with cutaneous squamous cell carcinoma (CSCC) at high ris

Introduction Epithelial ovarian cancer (EOC) is the leading cause of mortality among all gynecologic cancers, with over 70% of patients diagnosed at an advanced stage and a 5-year survival rate of approximately 40% (1). Systemic therapy has evolved with the introduction of bevacizumab, a monoclonal antibody targeting vascular endothelial growth fac

Introduction Bevacizumab is a humanized monoclonal antibody targeting all circulating vascular endothelial growth factor A (VEGF-A) isoforms, preventing VEGF-A from binding to vascular endothelial growth factor receptors (VEGFR) and thereby inhibiting angiogenesis (1). By normalizing tumor vasculature, bevacizumab enhances the delivery of cytotoxic

As artificial intelligence becomes a powerful force in modern medicine, one question stands out — how can it be used responsibly in clinical practice? Join us for an engaging session, where global leaders will share their perspectives on integrating AI ethically, effectively, and safely into day-to-day medical decision-making. Speakers: Dr Amit Kum

Hello, and a warm welcome to MedX, where we bring you the latest news and insights from the world of medicine.  Breakthroughs in Immune Tolerance Earn 2025 Nobel Prize in Immunology The 2025 Nobel Prize in Physiology or Medicine has been awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their pioneering work on peripheral immune tole

Introduction Liquid biopsy has transformed the diagnostic approach in oncology by providing non-invasive access to tumor-derived molecular material. Circulating cell-free DNA (cfDNA), including circulating tumor DNA (ctDNA), has been widely implemented, yet limitations such as fragmentation and short half-life constrain its sensitivity, particularl

In this engaging KOL (Key Opinion Leader) interview, we sit down with Dr. Raman Narang, a leading Oncologist from Delhi, India, to explore how Precision Oncology is transforming cancer diagnosis and treatment. Dr. Narang explains how advances in genomics, molecular profiling, targeted therapies, and personalised treatment plans are not only improvi